School of Medicine
Showing 21-30 of 94 Results
-
David Tehrani, MD, MS
Affiliate,
BioDr. Tehrani is a board-certified, fellowship-trained interventional cardiologist with Stanford Health Care Tri-Valley in the East Bay.
He is focused on building long-term relationships with his patients and their families, while sharing his evidence-based expertise in the noninvasive and minimally invasive management of cardiovascular disease. He takes pride in forming care plans based on mutual decision-making.
Dr. Tehrani’s research interests include cutting-edge technology and advancements in medical management of cardiovascular disease. His clinical research studies and funded clinical research trials have focused on cardiovascular biomarkers, coronary physiology, cardiac hemodynamics, cardio-oncology, and procedural closure devices. His research background has been instrumental in helping him provide individualized, evidence-based care plans for conditions ranging from advanced heart failure to complex coronary disease.
Dr. Tehrani has an extensive clinical research background, with over 40 peer-reviewed publications in top cardiology journals. He has done over 30 presentations at conferences, including the American Heart Association (AHA) and American College of Cardiology (ACC) national meetings.
Dr. Tehrani is a member the American College of Cardiology, the American College of Physicians, the American Heart Association, the Heart Failure Society of America, and the International Society of Heart and Lung Transplantation. -
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Valerie Teng
Clinical Associate Professor, Medicine - Primary Care and Population Health
BioDr. Valerie Teng is a board certified family physician with special interests in preventative medicine and women's health. Her experiences in caring for patients with chronic conditions, such as diabetes and hypertension, have fueled her desire to partner with patients to enter healthier lifestyles. She is also passionate about providing comprehensive care to patients of all ages, including newborns and teens.
During her residency training, Dr. Teng explored many opportunities in medical education through the O’Connor-Stanford Leaders in Education Residency (OSLER) program. She is delighted to continue in medical education as a part of the faculty at Stanford Family Medicine. -
Stefano Testa, MD
Instructor, Medicine - Oncology
BioDr. Stefano Testa is a board-certified, fellowship-trained medical oncologist with Stanford Health Care. He is also a clinical instructor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Testa specializes in treating patients with sarcomas and other solid tumors using cellular therapy approaches. He has expertise in adoptive T-cell therapies, including chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR) therapies.
As a physician-scientist, Dr. Testa focuses on developing next-generation cellular therapies for solid tumors, particularly sarcomas. His research goal is to identify targets for adoptive T-cell therapies in solid tumors, including soft tissue and bone sarcomas, and on novel synthetic biology approaches to enhance the effectiveness of T-cell therapies against solid tumors.
Dr. Testa has authored numerous peer-reviewed publications in leading medical journals, including Immunity, Cancer Discovery, JAMA Network Open, Genome Medicine, and Biomacromolecules. He has presented his research at national and international scientific meetings, including the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting.
Dr. Testa is a member of the American Society of Clinical Oncology (ASCO), Connective Tissue Oncology Society (CTOS), the American Society of Hematology (ASH), and the Society for Immunotherapy of Cancer (SITC).
